Navigation Links
Convoy Therapeutics Granted Patent for Proprietary SPACE Technology
Date:9/25/2013

l stages of formulation to optimize long-term stability for scale up and completion of non-clinical toxicology. With written confirmation from the FDA that the 505(b)(2) pathway is appropriate for this product, the company anticipates a market launch in Q3, 2016.

The Convoy delivery platform represents a major leap forward in the topical delivery of active compounds. Convoy’s platform can potentially be used in dermatological products for the treatment of skin cancers, skin care and cosmetics, cosmeceuticals, and the reformulation of existing molecules for better penetration and retention in the skin.

Convoy Therapeutics is a subsidiary of the ACTUS Biotechnologies accelerator, an organization dedicated to accelerating innovative novel technologies to commercialization. The company was founded in 2011 based upon technology originally developed by Dr. Samir Mitragotri and his laboratory at the University of California Santa Barbara. More information can be found at http://www.convoytx.com. Information about ACTUS Biotechnologies can be found at http://www.actusbiotech.com.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11156464.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Convoy Therapeutics to Present at 2013 Rocky Mountain Life Science Investor and Partnering Conference
2. Convoy Therapeutics Announces the Relaunch of Their Interactive Website
3. Lightlake Therapeutics Commences Two-Week Patient Trial for Treatment of Opioid Overdose with National Institute on Drug Abuse (NIDA)
4. Moderna Therapeutics Named a "Fierce 15" Biotech Company for 2013
5. Protagonist Therapeutics Expands Series B Financing to $18 Million with Addition of $4 Million from Pharmstandard
6. PTC Therapeutics to Present at European Pediatric Neurology Society Congress
7. Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS Pharmaceuticals Inc., and InterMune Inc.
8. Adheron Therapeutics Names New Senior Leadership
9. Case Report Suggests Microbiome Therapeutics NM504 May Improve Tolerability of Metformin While Improving Blood Glucose Control
10. Echo Therapeutics Sends Response to Shareholder Letter
11. Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 Pharma Packaging ... position themselves for their 89th year in ... encoding, Pharma Packaging Solutions is preparing packaging ... software and new procedures. Establishing training and ... Practices (cGMP), Pharma Packaging Solutions will be ...
(Date:9/16/2014)... 16, 2014  LABSCO, the leading specialty sales ... hospitals, physician office laboratories and alternate healthcare settings ... 2014, it will serve as Siemens Healthcare Diagnostics, ... and as a semi-exclusive sales distributor in specified ... United States . LABSCO will be ...
(Date:9/16/2014)...  Ascendis Pharma A/S, a biotechnology company that ... unmet medical needs, today announced positive interim results ... evaluate once-weekly TransCon Growth Hormone in children with ... results will be presented at the 7th International ... held October 15-18, 2014, in Singapore.  ...
(Date:9/16/2014)... 16, 2014 BCC Research reveals ... STEM CELLS , the global market for stem cells ... 2018, with a five-year compound annual growth rate (CAGR) ... the Americas with growth projections of $2.2 billion in ... (Logo: http://photos.prnewswire.com/prnh/20140805/700528) , Unlike other potential applications ...
Breaking Biology Technology:Adding Serialization Capabilities and Expanded Capacity, Pharma Packaging Solutions Is Preparing for 89th Year of Business 2LABSCO Secures Alliance With Siemens Healthcare Diagnostics 2LABSCO Secures Alliance With Siemens Healthcare Diagnostics 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 2Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 3
... OF INDUSTRY, Calif. and HONG KONG, June 30 EFT BioTech ... has successfully completed its inaugural Taiwan Strait passenger voyage which has ... the Taiwan Sun, and the Qatar Tribune. The article states: ... with China on Sunday, making it the first such cross-strait service ...
... Mass., June 30 Microfluidics, a wholly owned ... MFLU), and Particle Sciences Inc. (PSI) have formed ... the most advanced and reliable nanotechnology and formulation ... Pharmaceutical Ingredients (APIs). , , Particle Sciences ...
... from the Taichung Harbor to Xiamen , China ... , , CITY OF INDUSTRY, Calif. and HONG ... announced today that the Company,s subsidiary, Excalibur International Marine Corporation, completed ... 2009. The voyage across the Taiwan Strait takes only 4 ...
Cached Biology Technology:Excalibur International Marine (49% Owned by EFT BioTech Holdings) Completes Inaugural Passenger Crossing of Taiwan Strait 2Excalibur International Marine (49% Owned by EFT BioTech Holdings) Completes Inaugural Passenger Crossing of Taiwan Strait 3Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization 2Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization 3EFT BioTech Holdings, Inc.'s Sea Vessel Completes Inaugural Passenger Voyage Across the Taiwan Strait 2EFT BioTech Holdings, Inc.'s Sea Vessel Completes Inaugural Passenger Voyage Across the Taiwan Strait 3
(Date:9/16/2014)... Johns Hopkins neuroscientists have discovered the "molecular brakes" that ... ear cochleas of mice. These "hair cells" translate sound ... brain and are interpreted as sounds. If the arrangement ... , A summary of the research will be published ... 16. , "The proteins Hey1 and Hey2 act as ...
(Date:9/16/2014)... the dinosaurs 66 million years ago decimated the evergreens ... than their deciduous peers, according to a study led ... journal PLOS Biology . , Applying biomechanical ... leaves of angiosperms flowering plants excluding conifers ... of a diverse plant community thriving during a 2.2 ...
(Date:9/16/2014)... Hesperides vessel returned to Spain culminating the around the ... clear picture of how the global ocean works and ... pollutants from the atmosphere is not limited to coastal ... of the planet, and it is already affecting the ... week in CSIC Residence for Researchers in Barcelona, in ...
Breaking Biology News(10 mins):Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 2The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 3
... is on the rise and may be problematic, according ... the December issue of Obstetrics & Gynecology, Erin Tracy, ... and may present potential pitfalls for patients and physicians. ... have no proven clinical validity whatsoever and are quite ...
... for advanced age-related macular degeneration, researchers from Harvard and ... the cure. A research report published in the December ... endostatin to mice significantly reduced or eliminated abnormal blood ... the disease causes blindness. Our study provides ...
... brain injury and using club drugs have in common" ... chemical chain reaction in the brain, leading to cell death, ... series of studies at UF over the past five years ... MDMA, and other forms of methamphetamine lead to the same ...
Cached Biology News:Direct-to-consumer advertising for genetic tests concerns physicians and may mislead patients 2New treatment for age-related macular degeneration within sight 2Club drugs inflict damage similar to traumatic brain injury 2Club drugs inflict damage similar to traumatic brain injury 3
Our original highly-purified, robust Taq Polymerase which delivers consistently high yields and minimal background...
A formulation of our Biolase DNA Polymerase which contains a Red Loading Dye...
... immunosorbent assay (ELISA) test kits are ... for the detection of drugs and/or their ... intended for forensic use only. It is ... by a quantitative method such as GC/MS. ...
... SUPERaseIn RNase Inhibitor (patent pending) is ... that noncovalently binds and inhibits the most ... B, C, 1 and T1. SUPERaseIn can ... contamination could be problematic. It is ideal ...
Biology Products: